G. Haig

发表

Exposure‐Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation

S. Preskorn, M. Hutmacher, R. Lalonde, 2009, Journal of clinical pharmacology.

Effect of pharmacist participation on a medical team on costs, charges, and length of stay.

G. Haig, L. A. Kiser, George M. Haig, 1991, American journal of hospital pharmacy.

Meropenem: A New Carbapenem Antimicrobial

G. Haig, R. Pryka, Randy D. Pryka, 1994, The Annals of pharmacotherapy.

Aprotinin Decreases Exposure to Allogeneic Blood During Primary Unilateral Total Hip Replacement*

R. Hall, J. Murkin, M. Comunale, 2000, The Journal of bone and joint surgery. American volume.

PMH4 ASSOCIATION BETWEEN CHANGES ON THE NEGATIVE SYMPTOM ASSESSMENT SCALE AND MEASUREES OF FUNCTIONAL OUTCOME IN SCHIZOPHRENIA

D. Velligan, L. Alphs, O. Leeuwenkamp, 2006 .

Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies

M. Hufford, D. Hilt, R. Keefe, 2014, Schizophrenia Research.

Preliminary effects of pagoclone, a partial GABAA agonist, on neuropsychological performance

B. Giordani, G. Haig, A. Caveney, 2008, Neuropsychiatric disease and treatment.

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.

S. Dutta, Jun Zhang, C. Locke, 2013, British journal of clinical pharmacology.

Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR)

E. Mohler, J. J. Lynch, W. Bracken, 2017, Pharmacology Biochemistry and Behavior.

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

A. Othman, W. Robieson, E. Bain, 2016, The American journal of psychiatry.

Evaluation of the Abuse Potential of Pagoclone, a Partial GABAA Agonist

H. de Wit, D. Feltner, G. Haig, 2006, Journal of clinical psychopharmacology.

Pathophysiology and Treatment of Urinary Tract Infections

G. Haig, R. Pryka, Kathleen R. Hagmeyer, 1991 .

Metronidazole in the treatment of chronic pressure sores and ulcers. A comparison with standard treatment in general practice.

G. Haig, P. Baker, 1981, The Practitioner.

Single‐Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children

D. Ouellet, E. Posvar, E. Randinitis, 2001, Journal of clinical pharmacology.

Increase in Serum Digoxin Concentrations After Indomethacin Therapy in a Full‐Term Neonate

G. Haig, E. Brookfield, 1992, Pharmacotherapy.

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

A. Othman, G. Haig, Jun Zhao, 2016, Neuropsychopharmacology.

A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.

A. Othman, W. Robieson, R. Lenz, 2014, Schizophrenia bulletin.

A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.

A. Othman, Y. Pritchett, R. Lenz, 2014, Journal of Alzheimer's disease : JAD.

Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin

James P. Young, L. Crofford, P. Mease, 2008, PAIN.

Randomized , Double-Blinded , Placebo-Controlled onotherapy Trial of Pregabalin in Patients With Fibromyalg esley

L. Arnold, I. Russell, James P. Young, 2008 .

The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

S. Dutta, C. Locke, A. Othman, 2014, British journal of clinical pharmacology.

A double-blind comparison of mefenamic acid and piroxicam in acute soft tissue injuries.

G. Haig, 1988, Current medical research and opinion.

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

Philip D. Harvey, E. Dunayevich, D. Goff, 2015, Schizophrenia bulletin.

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.

A. Othman, E. Bain, G. Haig, 2017, The Journal of clinical psychiatry.

Placebo Response and Practice Effects in Schizophrenia Cognition Trials

Philip D. Harvey, D. Hilt, D. Umbricht, 2017, JAMA psychiatry.

Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid

D. Feltner, G. Haig, 2011, Journal of psychopharmacology.

Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers

B. Corrigan, E. Posvar, R. Boyd, 2010, Journal of clinical pharmacology.

Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients

E. Dunayevich, D. Hilt, D. Umbricht, 2017, Schizophrenia Research.

The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

S. Dutta, C. Locke, A. Othman, 2014, British journal of clinical pharmacology.

Pharmacokinetic Interaction of Gabapentin and Naproxen in Rats and Humans

E. Randinitis, D. Wesche, P. Knowlton, 2003 .

Portable thermogram technique for topically applied benzydamine cream in acute soft-tissue injuries.

G. Haig, 1986, International journal of tissue reactions.